Immunic, Inc. held its annual meeting of stockholders on June 29, 2026. Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing the authorized shares by 6,000,000, bringing the total to 8,644,887 shares. The company's stockholders elected Michael Bonney, Thorvald Nagel, and Dr. Richard Rudick as Class III Directors. The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. A quorum of 8,885,263 shares was present out of 13,621,483 shares entitled to vote.